How have the shares performed?
Cellectis S.A. (CLLS) saw an uptrend of 4.45% in the recent trading with $16.21 being its most recent. The current price level -53.30% lower than the highest price of $34.71 marked by the stock while trading over the past 52-weeks, whereas it is 13.75% higher than the lowest price of $14.25 the company dropped to over past 52-weeks. The latest news story on CLLS appeared in GlobeNewswire under the title “Cellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T” on May-11-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -20.62% below one month high and is +13.75% above of the lowest during that time. Looking into the simple moving average, Cellectis S.A. (CLLS)’s stock stands at a SMA-50 of $18.71 while that of 5-day is reading $15.77.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and CLLS’s SMA-200 as of now is $21.50.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 14 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.50 for the stock.
Cellectis S.A. Earnings – What Happened With CLLS
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Cellectis S.A. (CLLS) last released financial results for the quarter that ended 3/30/2021, posting a surprise factor of 65.40% for net revenue. During the reported three-month period, company’s sales were $21.25 billion while analysts on average were estimating the same to be $11.1 million.
CLLS – Cellectis S.A. Stock Earnings Estimates
The perspective of Cellectis S.A. (NASDAQ:CLLS)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.81 for stock’s EPS in the current quarter. 9 analysts covering the stock at Wall Street were agreed upon that EPS consensus. Company’s EPS for the last quarter was -0.28.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 42.87 million. CLLS does have institutional investors; and they hold 36.80% of the stock.
Cellectis S.A. – Insider Activity and Holdings
As on Mar 30, 2021, ARK Investment Management, LLC was the top most holder in Cellectis S.A. (NASDAQ:CLLS) with an ownership of 5.12 million shares of the company or 11.26% of the stake worth $103.43 million. The filing also reveals Capital International Investors as the second largest holder in the company with a control over 2.95% of the outstanding shares. Its stake is worth $27.07 million for having 1.34 million shares in hand.
Credit Suisse AG also came holding a key position in the company during the recent quarter and it now holds 2.64% of the outstanding shares. With this there are now 108 institutions which have possession in CLLS’s shares.
Currently, the stock has been recommended as Strong Buy by 14 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.50 for the stock.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Cellectis S.A. was 6.06 while posting a debt to equity ratio of 0.41. The count was 36.28 for long-term debt to equity ratio.
Cellectis S.A.’s return on equity, or ROE, is -39.10%, compared to the industry average of -41.48% for Healthcare – Biotechnology. Although this indicates that CLLS uses its equity well, the metric will vary significantly depending on the industry.
Technical Analysis of Cellectis S.A. (NASDAQ:CLLS) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Cellectis S.A. (CLLS), we notice that the stock’s 20-day average volume is at 222,230 shares and 100% of short term indicators are suggesting the stock as Sell. Medium term indicators at an average of 100% are spotting the stock at Sell with its 50-day average volume of 295,690 shares. And to end, CLLS’s 100-day average volume is 383,289 shares with 50% of the long-term indicators pointing towards Sell for the stock.